Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study
05:45pm, Tuesday, 25'th Jan 2022 Zacks Investment Research
Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
05:48pm, Monday, 24'th Jan 2022 Zacks Investment Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients
03:30pm, Monday, 24'th Jan 2022 Zacks Investment Research
Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.
BioDelivery (BDSI) Stock Up on Raised Guidance for 2021
03:49pm, Friday, 21'st Jan 2022 Zacks Investment Research
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
03:21pm, Friday, 21'st Jan 2022 Zacks Investment Research
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis
04:31pm, Thursday, 20'th Jan 2022 Zacks Investment Research
Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
04:28pm, Thursday, 20'th Jan 2022 Zacks Investment Research
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA
03:41pm, Thursday, 20'th Jan 2022 Zacks Investment Research
Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
01:28pm, Thursday, 20'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In Endometrial Cancer
Eisai Co.
Zacks.com featured highlights include: Alkermes, Tesla, Nucor Corp. and GoPro
11:48am, Thursday, 20'th Jan 2022 Zacks Investment Research
Alkermes, Tesla, Nucor Corp. and GoPro are highlighted in this Screen of the Week article.
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down
04:29pm, Wednesday, 19'th Jan 2022 Zacks Investment Research
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
Phillips (PHG) Blends 3D Mapping With Zenition, Aids Prospects
04:09pm, Wednesday, 19'th Jan 2022 Zacks Investment Research
Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.
4 Top-Ranked Liquid Stocks to Boost Portfolio Returns in 2022
02:14pm, Wednesday, 19'th Jan 2022 Zacks Investment Research
Here are four top-ranked liquid stocks, Alkermes (ALKS), Tesla (TSLA), Nucor (NUE) and GoPro (GPRO), which investors can tap for healthy returns.
4 Top-Ranked Liquid Stocks to Boost Portfolio Returns in 2022
10:45am, Wednesday, 19'th Jan 2022
Here are four top-ranked liquid stocks, Alkermes (ALKS), Tesla (TSLA), Nucor (NUE) and GoPro (GPRO), which investors can tap for healthy returns.
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
07:00am, Tuesday, 18'th Jan 2022
DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineere
